Affiliations: [a] Jess and Mildred Fisher Center for Familial Cancer Research, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC, USA | [b] Department of Pediatrics, University of Vermont College of Medicine, Familial Cancer Program Office Vermont Cancer Center, Burlington, VT, USA | Georgetown University, 3300 Whitehaven Street, NW, Suite 4100, Washington, DC 20007, USA
Correspondence:
[*]
Corresponding author: Georgetown University, 3300 Whitehaven Street, NW; Suite 4100, Washington, DC 20007, USA. Tel.: +1 202 687 2733; Fax: +1 202 687 8444; E-mail: [email protected]
Abstract: The process of genetic testing is often deemed a family affair. Several studies have indicated that individuals undergo BRCA1/2 testing not only to learn about their own cancer risks and options for screening and prevention, but also to gather information for potentially at-risk relatives. However, many individuals are not prepared for the medical and emotional implications that accompany the genetic testing process. This can be complicated by a moral or ethical obligation to disclose result status to other family members. Several characteristics including gender, BRCA1/2 carrier status, and cultural and ethnic background may influence the communication process between the proband and his/her potentially at-risk kin. In addition, the age of family members and their degree of relatedness may affect whether or not they are told the results of their relative's genetic testing. While genetic providers have an obligation to inform individuals of the implications of BRCA1/2 test results for at-risk relatives, they must also strive to respect and maintain autonomy and confidentiality. This paper will examine the characteristics that influence the disclosure of BRCA1/2 test results to relatives. In addition, methods of post-test support and follow-up to facilitate the disclosure process for patients and their family members as well as foster positive communication, will be discussed.
Keywords: BRCA1, BRCA2, family communication, support, genetic testing, breast and ovarian cancer
DOI: 10.3233/BD-2007-27108
Journal: Breast Disease, vol. 27, no. 1, pp. 127-136, 2007
